Retinal Vein Occlusion – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Retinal Vein Occlusion – Drugs In Development, 2024 report and make more profitable business decisions.
Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age.
The Retinal Vein Occlusion drugs in development market research report provide comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Retinal Vein Occlusion | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 37 molecules, with 37 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Retinal Vein Occlusion therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Retinal Vein Occlusion pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Retinal Vein Occlusion treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAffaMed Therapeutics US Inc
Allgenesis Biotherapeutics Inc
ANBITION Srl
Annexin Pharmaceuticals AB
AsclepiX Therapeutics Inc
AskGene Pharma Inc
Avirmax Inc
Calpain Therapeutics Pty Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chugai Pharmaceutical Co Ltd
Drive Therapeutics LLC
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Glaukos Corp
Huabo Biopharm (Shanghai) Co Ltd
KALA BIO Inc
Luye Pharma Group Ltd
Novartis AG
Novelty Nobility Inc
Ocular Therapeutix Inc
Oculis Holding AG
Outlook Therapeutics Inc
Oxular Ltd
Perfuse Therapeutics Inc
RevOpsis Therapeutics Corp
Ripple therapeutics Corp
SIFI SpA
Thea Open Innovation SASU
Theratocular Biotek Co Ltd
Uni-Bio Science Group Ltd
Valitor Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Retinal Vein Occlusion reports